Phanthaboon WangpatharawanitSomnuek SungkanuparphMahidol University2018-12-112019-03-142018-12-112019-03-142016-09-15Clinical Infectious Diseases. Vol.63, No.6 (2016), 818-82015376591105848382-s2.0-84995467105https://repository.li.mahidol.ac.th/handle/123456789/41150© 2016 The Author. A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.Mahidol UniversityMedicineSwitching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled TrialConference PaperSCOPUS10.1093/cid/ciw395